FutureScot
Health & Care

Glasgow ultrasound sensor specialist signs partnership agreement with US medtech firm

Novosound's Dave Hughes, left, and Lishan Aklog. Photograph supplied

A Glasgow ultrasound sensor specialist has signed a partnership agreement with a US medtech firm to develop technology aimed at advancing intravascular imaging.  

Novosound, which brings its technology to emerging industrial and medical applications, will work with Nasdaq-listed company PAVmed Inc., as it expands into the North American healthcare market.

Dave Hughes, CEO and co-founder of Novosound, said: “PAVmed has a strong track record in delivering commercial stage medical technology across medical devices, diagnostics, and digital health – the group is the ideal partner for Novosound as we increasingly gain traction in the international healthcare sector.”

Lishan Aklog, M.D., chairman and chief executive officer of PAVmed, said: “We believe Novosound’s proprietary ultrasound technology has the potential to be a once-in-a-generation breakthrough in medical imaging. We are excited to partner with Novosound with the goal of revolutionising the global intravascular imaging market.” 

Novosound recently secured its latest investment, a £3.7 million round led by Par Equity, supported by Foresight Group (via the Foresight Williams Technology EIS Fund), Kelvin Capital, and Scottish Enterprise.

Paul Munn, partner, Par Equity, said: “Novosound has developed best-of-class remote sensor technology that is applicable across multiple sectors, the company continues to rack up international business wins including most recently with PAVmed, and Par is pleased to continue to support Dave and his team in the months and years ahead.”  

Novosound’s patented thin-film manufacturing process, which eliminates conventional limitations in ultrasound sensors including the high cost of high-resolution imaging, also underpins the company’s pioneering non-destructive testing (NDT) products – the Kelpie, Belenus, and Nebula.

The company has announced a series of international contract wins over the last twelve months, including with aerospace groups BAE Systems and GE Aviation, and Israeli-based digital health company dSound.  

Novosound will be exhibiting its wireless wearable ultrasound platform at CES 2023 – the world’s largest consumer technology show – in Las Vegas between 5-8 January.  

Related posts

Too much screen time associated with cancer and heart disease in new study

Kevin O'Sullivan
May 28, 2018

iPads to help visually impaired children in Scotland use the internet

Poppy Watson
August 10, 2021

‘Let’s inspire inclusive, innovative healthcare on International Women’s Day’

InnoScot Health
March 8, 2024
Exit mobile version